FDA Brief

Warning letters Drugs

FDA warning letter to

Terramed

High riskIssued Oct 1Posted Oct 6Center for Drug Evaluation and Research (CDER)

FDA warned Terramed that four STI-related washes and ointments are unapproved new drugs sold online.

What happened

FDA reviewed Terramed's website https://terramed.info in July 2026. It found four products—Genital Herpes Intimate Wash, HerpCare Ointment, HerpCare Spray, and HerpCare Genital Wart Remover Ointment—marketed with claims to relieve or treat genital herpes and genital warts. FDA says no OTC drug is approved for any STI and that these are unapproved new drugs.

What FDA found

  1. The products are drugs because their labeling claims they treat, cure, mitigate, or prevent disease or affect body structure or function.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. FDA says the products are new drugs not generally recognized as safe and effective, and no FDA-approved application is in effect for them.

    FD&C Act sections 201(p) and 505(a), 21 U.S.C. 321(p) and 355(a)
  3. Selling or shipping these unapproved drugs in interstate commerce violates the FD&C Act.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  4. Calling HerpCare Ointment and Spray homeopathic does not exempt them; FDA says lemongrass is not listed in the Homeopathic Pharmacopeia of the United States.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  5. FDA says it has not approved any OTC drug for treatment, cure, mitigation, or prevention of any STI.

What FDA wants

FDA asks Terramed to respond in writing within 15 business days to FDAAdvisory@fda.hhs.gov with the steps taken to correct the violations, how recurrence will be prevented, and supporting documents, using reference number 735070.

Who should pay attention

  • online sellers of intimate-care products with disease claims
  • retailers and marketplaces listing STI or wart treatments
  • consumers who might use these products instead of medical care

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk